NeoGenomics (NASDAQ:NEO) Given New $18.00 Price Target at Piper Sandler

NeoGenomics (NASDAQ:NEOGet Rating) had its price target dropped by stock analysts at Piper Sandler from $19.00 to $18.00 in a report issued on Monday, The Fly reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Piper Sandler’s target price indicates a potential upside of 59.86% from the company’s previous close.

NEO has been the subject of several other research reports. Needham & Company LLC lowered NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, August 22nd. StockNews.com raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, November 11th. Cowen increased their price objective on NeoGenomics to $18.00 in a research note on Monday, August 15th. The Goldman Sachs Group increased their price objective on NeoGenomics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, August 10th. Finally, BTIG Research lowered NeoGenomics to a “neutral” rating in a research note on Monday, August 15th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, NeoGenomics presently has an average rating of “Hold” and a consensus price target of $19.00.

NeoGenomics Stock Up 2.8 %

Shares of NEO opened at $11.26 on Monday. The firm has a market cap of $1.42 billion, a P/E ratio of -8.53 and a beta of 0.90. The stock has a 50 day simple moving average of $8.64 and a two-hundred day simple moving average of $9.04. The company has a debt-to-equity ratio of 0.53, a current ratio of 7.10 and a quick ratio of 6.82. NeoGenomics has a 1 year low of $6.00 and a 1 year high of $41.15.

Institutional Trading of NeoGenomics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alliancebernstein L.P. lifted its stake in NeoGenomics by 29.3% in the third quarter. Alliancebernstein L.P. now owns 287,932 shares of the medical research company’s stock worth $2,479,000 after acquiring an additional 65,315 shares during the period. State Street Corp lifted its stake in NeoGenomics by 2.8% in the third quarter. State Street Corp now owns 4,217,160 shares of the medical research company’s stock worth $36,310,000 after acquiring an additional 116,802 shares during the period. Algert Global LLC lifted its stake in NeoGenomics by 9.2% in the third quarter. Algert Global LLC now owns 93,332 shares of the medical research company’s stock worth $804,000 after acquiring an additional 7,892 shares during the period. Twinbeech Capital LP bought a new position in NeoGenomics in the third quarter worth $514,000. Finally, Trexquant Investment LP bought a new position in NeoGenomics in the third quarter worth $250,000. Hedge funds and other institutional investors own 92.75% of the company’s stock.

NeoGenomics Company Profile

(Get Rating)

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.

Featured Articles

The Fly logo

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.